Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Effects of Hirudotherapy, Phytotherapy, and Forest Therapy in Adults With Reduced Work Capacity or Special Needs (CAM-HPMT)

13 de julio de 2026 actualizado por: Laura Zaliene, Klaipėda University

Evaluation of the Biological Effects of Complementary and Alternative Health Care Services, Including Forest Therapy, Phytotherapy, and Hirudotherapy, in Individuals With Reduced Work Capacity and/or Special Needs

This interventional study will evaluate the effects of three complementary and alternative health care services-forest therapy, phytotherapy, and hirudotherapy-in individuals with a participation level below 55% and/or special needs. Participants will be assigned to one of three intervention groups or to a control group. The study will assess changes in blood pressure, body composition, handgrip strength, psychological well-being, perceived stress, and sleep quality before and after the intervention period. Safety, accessibility, feasibility, and acceptability of the services will also be evaluated. The findings will be used to develop standardized and evidence-informed recommendations for providing these services to people with reduced participation and/or special needs.

Descripción general del estudio

Descripción detallada

This randomized controlled interventional study will evaluate the biological, functional, and psychosocial effects of complementary and alternative health care services in individuals with a participation level below 55% and/or special needs. The study is designed to generate evidence for the development of standardized, accessible, and evidence-informed protocols for forest therapy, phytotherapy, and hirudotherapy.

A total of 100 participants will be enrolled and allocated to four groups of approximately 25 participants each: a phytotherapy group, a forest therapy group, a hirudotherapy group, and a control group receiving no study-related complementary and alternative health care intervention. Participants in the phytotherapy group will receive three phytotherapy sessions, participants in the forest therapy group will receive ten forest therapy sessions, and participants in the hirudotherapy group will receive six hirudotherapy sessions. The interventions will be delivered by appropriately qualified and licensed practitioners in accordance with Lithuanian legal and professional requirements.

Assessments will be conducted before and after the intervention period. Physiological and functional assessments will include blood pressure, body composition, and handgrip strength. Psychosocial outcomes will include psychological well-being, perceived stress, and sleep quality, assessed using standardized questionnaires, including the WHO-5 Well-Being Index, the 10-item Perceived Stress Scale, and the Pittsburgh Sleep Quality Index. Pre-intervention and post-intervention outcomes will be compared within and between the intervention and control groups.

The study will also evaluate the feasibility, accessibility, safety, and acceptability of providing these services to individuals with reduced participation and/or special needs. Reasonable accommodations may include accessible locations, adapted information formats, assistance with transportation or mobility, and support from accompanying persons when required.

Participant safety will be monitored throughout the study. Eligibility, contraindications, and potential risks will be assessed before the interventions. Any adverse events or unexpected reactions will be documented and evaluated. Particular attention will be given to contraindications and safety requirements associated with phytotherapy and hirudotherapy.

The results will be used to prepare standardized methodological materials and practical recommendations for complementary and alternative health care practitioners, health promotion programs, and social inclusion services.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

100

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Klaipėda County
      • Klaipėda, Klaipėda County, Lituania, LT-92294
        • Klaipeda University, Faculty of Health Sciences

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

Individuals with a participation level below 55% and/or officially recognized special needs.

Ability and willingness to participate in the study procedures and assigned intervention.

Provision of written informed consent by the participant or, where applicable, by a legally authorized representative.

Ability to complete the planned assessments independently or with reasonable assistance.

Medical condition sufficiently stable to participate in the assigned complementary and alternative health care intervention.

Willingness to attend baseline and post-intervention assessments and the scheduled intervention sessions.

Exclusion Criteria:

Acute illness, fever, active infection, or clinically unstable health condition at the time of enrollment.

Any medical condition that, in the investigator's or intervention provider's judgment, would make participation unsafe.

Known contraindication to the intervention to which the participant may be assigned.

Current participation in another interventional study that could affect the study outcomes.

Inability to provide informed consent and absence of a legally authorized representative.

Inability to comply with the study procedures or intervention schedule despite reasonable accommodations.

Planned major medical procedure or substantial change in treatment during the study period that could influence the study outcomes.

Additional intervention-specific exclusion criteria:

Phytotherapy: known allergy or hypersensitivity to the planned herbal products; clinically relevant interactions with current medications; pregnancy or breastfeeding, when relevant to the selected herbal product; severe hepatic or renal impairment where the planned preparation may be contraindicated.

Hirudotherapy: bleeding disorders; clinically significant anemia; current anticoagulant or antiplatelet therapy when considered unsafe by the treating clinician; immunodeficiency; active skin infection or lesion at the planned application site; known allergy to leech-related substances; other contraindications identified by the licensed hirudotherapy practitioner.

Forest therapy: acute condition limiting safe participation outdoors; uncontrolled cardiovascular or respiratory symptoms; severe mobility, cognitive, behavioral, or sensory limitations that cannot be safely accommodated; severe allergy or environmental sensitivity relevant to the planned setting.

-

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Investigación de servicios de salud
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Phytotherapy Group
Participants assigned to this arm will receive three phytotherapy sessions delivered by a qualified complementary and alternative health care practitioner. The services will use legally permitted and appropriately sourced herbal products in accordance with Lithuanian professional and safety requirements. Physiological, functional, and psychosocial outcomes will be assessed before and after the intervention period.
Participants assigned to the phytotherapy arm will receive three individualized phytotherapy sessions delivered by a qualified complementary and alternative health care practitioner. The intervention may include assessment, selection, and use of legally permitted herbal preparations or herbal products appropriate to the participant's health status and special needs. Products will not be presented as investigational medicinal products. Contraindications, possible interactions, tolerability, and adverse reactions will be assessed and monitored throughout the intervention period.
Experimental: Forest Therapy Group
Participants assigned to this arm will receive ten structured forest therapy sessions delivered by a qualified forest therapy practitioner. Sessions will be adapted to participants' functional abilities and special needs and will be conducted in accessible natural environments. Physiological, functional, and psychosocial outcomes will be assessed before and after the intervention period.
Participants assigned to the forest therapy arm will receive ten structured forest therapy sessions delivered by a qualified forest therapy practitioner. Sessions will take place in accessible natural or forest environments and may include guided slow walking, sensory awareness, breathing, relaxation, mindful attention, and reflective activities. Session content and pace will be adapted to participants' functional abilities and special needs. Attendance, tolerability, and any adverse events will be documented.
Experimental: Hirudotherapy Group
Participants assigned to this arm will receive six hirudotherapy sessions delivered by a qualified and licensed hirudotherapy practitioner. Eligibility and contraindications will be assessed before treatment, and participant safety and adverse events will be monitored throughout the intervention period. Physiological, functional, and psychosocial outcomes will be assessed before and after the intervention period.
Participants assigned to the hirudotherapy arm will receive six hirudotherapy sessions delivered by a qualified and licensed practitioner. Before the intervention, eligibility and contraindications will be assessed. Medicinal leeches will be applied according to an individualized protocol, taking into account the participant's health condition and safety requirements. Participants will be monitored for bleeding, local skin reactions, infection, allergic reactions, and other adverse events during and after each session.
Sin intervención: Control Group
Participants assigned to this arm will not receive a study-related complementary and alternative health care intervention during the study period. They will undergo the same baseline and post-intervention assessments as participants in the intervention groups.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Systolic Blood Pressure
Periodo de tiempo: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in resting systolic blood pressure from baseline to the post-intervention assessment. Blood pressure will be measured in millimeters of mercury (mmHg) using a standardized procedure. A lower post-intervention value compared with baseline will indicate a reduction in systolic blood pressure.
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Diastolic Blood Pressure
Periodo de tiempo: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in resting diastolic blood pressure from baseline to the post-intervention assessment. Blood pressure will be measured in millimeters of mercury (mmHg) using a standardized procedure. A lower post-intervention value compared with baseline will indicate a reduction in diastolic blood pressure.
Baseline and after completion of the intervention period, approximately 3 months after baseline

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Psychological Well-Being Assessed With the WHO-5 Well-Being Index
Periodo de tiempo: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in psychological well-being from baseline to the post-intervention assessment, measured using the 5-item World Health Organization Well-Being Index (WHO-5). The raw score ranges from 0 to 25, with higher scores indicating better psychological well-being. The raw score may also be multiplied by 4 to obtain a percentage score ranging from 0 to 100.
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Perceived Stress Assessed With the PSS-10
Periodo de tiempo: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in perceived stress from baseline to the post-intervention assessment, measured using the 10-item Perceived Stress Scale (PSS-10). The total score ranges from 0 to 40, with higher scores indicating greater perceived stress.
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Sleep Quality Assessed With the Pittsburgh Sleep Quality Index
Periodo de tiempo: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in sleep quality from baseline to the post-intervention assessment, measured using the Pittsburgh Sleep Quality Index (PSQI). The global score ranges from 0 to 21, with higher scores indicating poorer sleep quality.
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Handgrip Strength
Periodo de tiempo: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in maximal handgrip strength from baseline to the post-intervention assessment. Handgrip strength will be measured in kilograms using a hand dynamometer under standardized testing conditions. Higher values indicate greater grip strength.
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Body Fat Percentage
Periodo de tiempo: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in body fat percentage from baseline to the post-intervention assessment, measured using a standardized body composition analyzer. Lower or higher values will be interpreted according to the participant's individual health status.
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Body Weight
Periodo de tiempo: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in body weight from baseline to the post-intervention assessment. Body weight will be measured in kilograms using a standardized body composition analyzer, with participants assessed under comparable measurement conditions.
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Body Mass Index
Periodo de tiempo: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in body mass index from baseline to the post-intervention assessment. Body mass index will be calculated as body weight in kilograms divided by height in meters squared and reported in kg/m².
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Skeletal Muscle Mass
Periodo de tiempo: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in skeletal muscle mass from baseline to the post-intervention assessment. Skeletal muscle mass will be estimated in kilograms using a standardized bioelectrical impedance body composition analyzer under comparable measurement conditions.
Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in Visceral Fat Level
Periodo de tiempo: Baseline and after completion of the intervention period, approximately 3 months after baseline
Change in visceral fat level from baseline to the post-intervention assessment. Visceral fat will be estimated using a standardized bioelectrical impedance body composition analyzer and reported according to the device-specific visceral fat rating scale. Lower scores indicate a lower estimated level of visceral fat.
Baseline and after completion of the intervention period, approximately 3 months after baseline

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Laura Zaliene, PhD, Klaipėda University

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de abril de 2026

Finalización primaria (Estimado)

20 de diciembre de 2026

Finalización del estudio (Estimado)

20 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

13 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

13 de julio de 2026

Publicado por primera vez (Actual)

16 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de julio de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir